By Colin Kellaher
Eyenovia on Thursday said it has signed a non-binding letter of intent to combine with clinical-stage pharmaceutical company Betaliq in an all-stock reverse merger.
Eyenovia said Betaliq investors will own about 83.7% of the combined company upon completion of the deal, while its current shareholders would own about 16.3%.
New York ophthalmic-technology company Eyenovia said the proposed transaction assumes a value of about $77 million for Betaliq and roughly $15 million for Eyenovia, which sports a market capitalization of about $3.51 million based on Wednesday's closing price of $1.67.
Trading in shares of Eyenovia was halted premarket on Thursday.
A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 20, 2025 07:20 ET (11:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。